728 x 90



  • Positive results from trial of SNG001 in COVID-19 patients

    Positive results from trial of SNG001 in COVID-19 patients0

    Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients Patients who received SNG001 had a 79% lower risk of developing severe disease compared to placebo Patients who received SNG001 were more than twice as likely to recover from COVID-19 as those on placebo Southampton, UK – 20 July 2020: Synairgen plc (LSE:

    READ MORE